Diplomat Pharmacy Inc (DPLO) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
76 |
Employees |
2,915 |
Revenues (TTM) (Millions $) |
5,206 |
Net Income (TTM) (Millions $) |
-649 |
Cash Flow (TTM) (Millions $) |
1 |
Capital Exp. (TTM) (Millions $) |
18 |
Diplomat Pharmacy Inc
Diplomat Pharmacy Inc. is a leading provider of specialty pharmacy and infusion services in the United States. The company was founded in 1975 and is headquartered in Flint, Michigan. Diplomat Pharmacy is a publicly traded company on the New York Stock Exchange (NYSE) under the ticker symbol DPLO.
Diplomat Pharmacy specializes in providing medication therapy management and clinical services to patients with complex and chronic conditions such as cancer, HIV/AIDS, hepatitis, multiple sclerosis, rheumatoid arthritis, and other autoimmune disorders. The company also provides specialty infusion services for patients who require medication through an intravenous route.
The company has a nationwide network of specialty pharmacies and infusion centers that allows it to provide personalized and convenient care to patients across the United States. Diplomat Pharmacy's team of experienced pharmacists and clinical staff work closely with patients, healthcare providers, and payers to ensure that patients receive the most effective and cost-efficient treatments available.
Diplomat Pharmacy places a strong emphasis on patient care, clinical excellence, and innovation. The company invests heavily in research and development to stay at the forefront of the latest medical treatments and technology. Diplomat Pharmacy also partners with healthcare providers and payers to develop customized solutions that improve patient outcomes and reduce healthcare costs.
Diplomat Pharmacy has received numerous awards and recognitions for its innovative and patient-centered approach to healthcare. The company has also been recognized for its commitment to diversity and inclusion, environmental sustainability, and corporate social responsibility.
In 2019, Diplomat Pharmacy was acquired by UnitedHealth Group, a leading diversified healthcare company. Under the ownership of UnitedHealth Group, Diplomat Pharmacy continues to provide high-quality specialty pharmacy and infusion services to patients across the United States.
Company Address: 4100 S. Saginaw Street Flint 48507 MI
Company Phone Number: 720-4450 Stock Exchange / Ticker: NYSE DPLO
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Hwh International Inc
The financial results for the fourth quarter of 2023 for HWH International Inc show a slight improvement in earnings per share compared to the previous year, but a decrease from the previous quarter. The revenue remained unchanged from both the previous year and the previous quarter. The company reported a net loss of $0.000 million for the quarter, which is a decrease from the corresponding quarter a year before. Looking at the fiscal year 2023 as a whole, HWH International Inc reported revenue of $0.00 million and earnings of $0.55 million. This indicates that the company was able to generate profits for the year despite experiencing a loss in the fourth quarter.
|
Petiq Inc
PETQ Reports Increased Loss Per Share for Recent Fiscal Period EAGLE, Idaho, Feb. 07, 2024 - PetIQ, Inc. (PetIQ or the Company) (Nasdaq: PETQ), a leading pet medication and wellness company, announced its financial results for the fourth quarter and full year ended December 31, 2023. Despite some unfavorable numbers, the company remains optimistic about its future performance. For the most recent fiscal period, PETQ reported a loss per share of $-0.60, compared to $-0.24 in the previous year. The Income per Share also fell from $0.02 to -$0.60 sequentially. However, there was a notable increase in revenue, which grew by 19.937% to $220.78 million from $184.08 million in the same quarter of the previous year.
|
Nu Skin Enterprises Inc
Nu Skin Enterprises Faces Significant Revenue and Profit Declines in Q4 2023 Nu Skin Enterprises Inc. (NYSE: NUS) recently released its fourth quarter and full-year 2023 financial results, which showed a significant decline in revenue and profits. In the fourth quarter of 2023, the company's revenue decreased by a staggering -6.518% to $488.30 million, compared to $498.27 million in the previous quarter. This decline in revenue directly impacted the company's profits, which plummeted by -87.26% to $0.15 per share, down from $1.16 per share in the corresponding quarter one year ago. The decline in revenue and profits is a cause for concern for Nu Skin Enterprises shareholders. The company's bottom-line also suffered, with a -87.27% decrease in net income from $57.215 million in the corresponding period a year before to $7.282 million in the fourth quarter of 2023. This significant decline in profits raises doubts about the company's ability to maintain its financial stability and sustainability.
|
Mckesson Corporation
McKesson Corporation, a leading healthcare services company, has experienced a significant increase in its stock performance in recent months. Over the past three months, the company's stock has improved by 15.42%. However, during the month of February, the stock dropped by 2.94%. Despite this dip, McKesson Corporation's stock has reached its 52-week high. One of the factors contributing to the fluctuation in McKesson Corporation's stock price is its financial performance. In the third quarter of the 2024 earnings season, the company experienced a decline in earnings per share (EPS) while revenue increased. EPS plummeted by -42.3% to $4.42 per share, while revenue showed an admirable increase of 14.765% to $80.90 billion compared to the same reporting season the previous year.
|
Cvs Health Corporation
CVS Health Corporation, a leading Pharmacy Services and Retail Drugstore company, experienced a slight decline in its shares during the month of February 2024. The shares dropped by -0.22%, bringing the year-to-date performance to -8.77%. Currently trading on the NYSE, CVS Health Corporation's shares are valued at 1% above its 52-week average. During the period from October to December 2023, CVS Health Corporation witnessed a reduction in its earnings per share (EPS) despite a significant increase in revenue. The profitability decreased by -9.26% to $1.59 per share, while the revenue grew extensively by 11.887% to $93.81 billion compared to the same period the previous year. This growth in revenue outpaced the top-line performance of most other companies in the Pharmacy Services and Retail Drugstore sector, as they reported an average revenue advance of 11.61% in the fourth quarter of 2023 compared to the previous year.
|
Per Share |
Current |
Earnings (TTM) |
-8.67 $ |
Revenues (TTM) |
68.95 $
|
Cash Flow (TTM) |
0.02 $ |
Cash |
0.11 $
|
Book Value |
1.74 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-8.67 $
|
Revenues (TTM) |
68.95 $ |
Cash Flow (TTM) |
0.02 $ |
Cash |
0.11 $
|
Book Value |
1.74 $ |
Dividend (TTM) |
0 $ |
|
|
|
|